Crohn's disease: modern aspects of anticytokine therapy

Cover Page

Cite item

Full Text

Abstract

A review of literature on topical issues in the treatment of inflammatory bowel diseases, such as Crohn's disease. It is based on the results of randomized studies conducted in the last 10 years. Considered terms such as “escape effect” and its causes, the transition from one anticytokine drug to another with the ineffectiveness of the first and the presence of the answer to it.

About the authors

V. A Akhmedov

Omsk State Medical University of the Ministry of Health of the Russian Federation

Email: v_akhmedov@mail.ru
д-р мед. наук, проф., зав. каф. мед. реабилитации ДПО ФГБОУ ВО ОмГМУ 644099, Russian Federation, Omsk, ul. Lenina, d. 12

I. N Orlov

Omsk State Medical University of the Ministry of Health of the Russian Federation

Email: igororlov1993@mail.ru
клин. ординатор каф. мед. реабилитации ДПО ФГБОУ ВО ОмГМУ 644099, Russian Federation, Omsk, ul. Lenina, d. 12

O. V Gaus

Omsk State Medical University of the Ministry of Health of the Russian Federation

ассистент каф. факультетской терапии профессиональных болезней ФГБОУ ВО ОмГМУ 644099, Russian Federation, Omsk, ul. Lenina, d. 12

References

  1. Воробьев Г.И., Халиф И.Л. Неспецифические воспалительные заболевания кишечника. М: Миклош, 2008.
  2. Sartor R.B. Pathogenesis ad immune mechanisms of chronic inflammatory bowel disease. Am J Gastroenterol 1997; 92 (Suppl. 12): 533-89.
  3. Scaldaferri F, Fiocchi C. Inflammatory bowel disease: Progress and current concepts of etiopathogenesis. J Dig Dis 2007; 8: 171-8.
  4. Breese E, Michie C, Nicholls S et al. Tumor necrosis factor alphaproducing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994; 106; 1455-66.
  5. Ассоциация колопроктологов России. Российская группа по изучению воспалительных заболеваний кишечника. Российские рекомендации по диагностике и лечению воспалительных заболеваний кишечника. М., 2012.
  6. Dignass A, Van Assche G, Lindsay J.O et al. European Crohn’s and Colitis Organisation (ECCO). The second European evidence - based Consensus on the diagnosis and management of Crohn’s disease: Current management. J Crohn’s Colitis 2010; 4 (1): 28-62.
  7. Белоусова Е.А. Реальные и потенциальные возможности лечения рефрактерных форм воспалительных заболеваний кишечника. Рус. мед. журн. 2005; 2: 88-96.
  8. Корниенко Е.А., Ломакина Е.А., Залетова Н.К., Фадина С.А. Возможности системных и топических стероидов в лечении воспалительных заболеваний кишечника у детей. Лечащий врач. 2010; 4: 82-5.
  9. Адлер Г. Болезнь Крона и язвенный колит. М.: ГЭОТАР-МЕД, 2001.
  10. Chey W.Y, Hussain A, Ryan C et al. Infliximab for refractory ulcerative colitis. Am Gastroenterol 2001; 96: 1860-6.
  11. Hanauer S.B, Stromberg U. Oral Pentasa in the treatment of active Crohn’s disease. Clin Gastroenterol Hepatol 2004; 2 (5): 379-88.
  12. Lichtenstein G.R, Hanauer S.B, Sandborn W.J. Practice Parameters Committee of American College of Gastroenterology. Management of Crohn’s diseaseinadults. Am J Gastroenterol 2009; 104 (2): 465-83.
  13. Prefontaine E, Sutherland L.R, Macdonald J.K, Cepoiu M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2009; 1: CD000067. doi: 10.1002/14651858. CD000067.pub2.
  14. Kaser A, Nieuwenhuis E, Glimcher L et al. Innate immunity in inflammatory bowel disease. Falk Symposium 2006; p. 23-4.
  15. Российские рекомендации по диагностике и лечению воспалительных заболеваний кишечника. М., 2012.
  16. Travis S, Van Assche G, Dignass A et al. On the second ECCO Consensus on Crohn`s disease. J Crohn’s Colitis 2010; 4: 1-6.
  17. Барановский А.Ю., Кондрашина Э.А., Харитонов А.Г. Прогноз неблагоприятного течения язвенного колита как показание к проведению антицитокиновой терапии. РЖГГК. 2012; 2; 63-9.
  18. Валуйских Е.Ю., Светлова И.О., Курилович С.А. и др. Полиморфизм генов регуляторов воспаления при болезни Крона и неспецифическом язвенном колите. Бюллетень СО РАМН. 2009; 2 (136); 81-9.
  19. Wilkins T, Jarvis K, Patel J. Diagnosis and management of Crohn’s disease. Am Fam Physician 2011; 84 (12): 1365-75.
  20. Molnár T, Farkas K, Nyári T et al. Frequency and predictors of loss of response to infliximab or adalimumab in Crohn’s disease after one - year treatment period - a single center experience. J Gastrointest Liver Dis 2012; 21 (3): 265-9.
  21. Kestens C, van Oijen M.G, Mulder C.L et al. Dutch Initiative on Crohn and Colitis (ICC). Adalimumab and infliximab are equally effective for Crohn’s disease in patients not previously treated with anti - tumor necrosis factor - a agents. Clin Gastroenterol Hepatol 2013; 11 (7): 826-31.
  22. Etchevers M.J, Orda I, Richart E. Optimizing the Use of Tumour Necrosis Factor Inhibitors in Crohn’s Disease: A Practical Approach. Drugs 2010; 70: 109-20.
  23. Thomson A.B, Gupta M, Freeman H.J. Use of the tumor necrosis factorblockers for Crohn’s disease. World J Gastroenterol 2012; 18 (35): 4823-54.
  24. Белоусова Е.А., Моисеев С.В. Инфликсимаб: 10 лет успешного применения при воспалительных заболеваниях кишечника. Клин. фармакология и терапия. 2010; 19 (1): 50-4.
  25. Targan S, Hanauer S, van Deventer S et al. A short - term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohns disease. N Engl J Med 1997; 337: 1029-35.
  26. Hanauer S, Feagan B, Lichtenstein G et al. Maintenance infliximab for Crohns disease: the ACCENT I randomized trial. Lancet 2002; 359 (9317): 1541-9.
  27. Bruce E, Sands M, Frank H et al. Infliximab maintenance therapy for fistulizing Crohns disease. N Engl J Med 2004; 350: 876-85.
  28. Hyams J, Crandall W, Kugathasan S et al. Induction and maintenance infliximab therapy for the treatment of moderate to - severe Crohns disease in children. Clin Gastroenterol Hepatol 2012; 10 (4): 391-9.
  29. Hanauer S.B, Sandborn W.J, Rutgeerts P et al. Human anti - tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 2006; 130 (2): 323-33.
  30. Sandborn W.J, Hanauer S.B, Rutgeerts P et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut 2007; 56 (9): 1232-9.
  31. Zorzi F, Zuzzi S, Onali S et al. Efficacy and safety of infliximab and adalimumab in Crohn’s disease: a single centre study. Aliment Pharmacol Ther 2012; 35 (12): 1397-407.
  32. Gisbert J.P, Panés J. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol 2009; 104 (3): 760-7.
  33. Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn’s disease. Aliment Pharmacol Ther 2011; 33 (9): 987-95.
  34. Allez M, Karmiris K, Louis E et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis 2010; 4: 355-66.
  35. De Ridder L, Rings E.H, Damen G.M et al. Infliximab dependency in pediatric Crohn’s disease: longterm follow - up of an unselected cohort. Inflamm Bowel Dis 2008; 14: 353-8.
  36. Oussalah A, Babouri A, Chevaux J.B et al. Adalimumab for Crohn’s disease with intolerance or lost response to infliximab: a 3-year singlecentre experience. Aliment Pharmacol Ther 2009; 29 (4): 416-23.
  37. Chaparro M, Andreu M, Barreiro - de Acosta M et al. Effectiveness of infliximab after adalimumab failure in Crohn’s disease. World J Gastroenterol 2012; 18 (37): 5219-24.

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies